Gilead says COVID-19 recovery drug hit primary target
Gilead Sciences Inc. said data from a U.S. study of its drug remdesivir showed the medication had met the primary endpoint in a trial of its effectiveness in treating COVID-19.
The company said in a statement that it is aware of positive data emerging from the National Institute of Allergy and Infectious Diseases’ study of remdesivir for treating the disease caused by the novel coronavirus.
Gilead shares were halted, but the news appeared to lift the entire U.S. stock market, with futures linked to major U.S. indexes jumping after the company’s statement was issued.
The U.S.-run trial looked at whether patients getting Gilead’s drug recovered from the disease faster than patients getting a placebo treatment plus standard care for the illness.
The trial, run by the National Institutes of Health, aimed to sign up about 800 patients to test the drug and give a definitive answer as to whether it can help treat the illness.
A NIAID representative didn’t immediately respond to a call seeking comment.Remdesivir, which was originally developed to treat other coronaviruses like SARS and has also been tested on Ebola, isn’t licensed or approved for use anywhere in the world.
More coronavirus coverage from Fortune:
—What the law says about forcing employees back to the office
—Alphabet and Facebook earnings are expected to be bad. The question is how bad?
—How the U.S. should invest in public health before reopening the economy
—Tech issues and backlogs hit the SBA’s second round of PPP loans
—There may be 22 hidden coronavirus hotspots in states poised to lift restrictions
—Coronavirus brought China’s travel industry to a standstill. Now it’s showing signs of life
—The coronavirus pandemic is impacting critical research into neuromuscular diseases
—PODCAST: How 2 CEOs outside of health care decided to pivot to fight COVID-19
—WATCH: Fortune’s top 10 heroes of the coronavirus pandemic
Subscribe to Outbreak, a daily newsletter roundup of stories on the coronavirus pandemic and its impact on global business. It’s free to get it in your inbox.